Results for this period
Third quarter1 January 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Higher revenue from the pharmaceutical business, increased advertising and sales promotion expenses, and the reversal of gains on the sale of investment securities, gains on the reversal of the foreign currency translation adjustment account and compensation received recorded in the same period of the previous year.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | 4,589 Millions of yen (YoY +8.5%) |
| Operating profit | 156 Millions of yen (YoY -51.7%) |
| Ordinary income | 171 Millions of yen (YoY -47.2%) |
| Profit attributable to owners of the parent | 169 Millions of yen (YoY -74.7%) |
| Net income per share | ¥3.36 |
| Equity ratio | End of the current fiscal period 74.8 / End of previous period 69.4 |
| Total assets | 11,408 Millions of yen |
| Net assets | 8,538 Millions of yen |
| Full-year earnings forecast | Net Sales 7,200 Millions of yen (YoY +12.5%) / Operating profit 500 Millions of yen (YoY +8.9%) / Ordinary income 520 Millions of yen (YoY +7.7%) / Profit attributable to owners of the parent 550 Millions of yen (YoY -40.4%) |
| Annual Dividend Forecast | 3.3 Yen → 3.5 Yen |
| Segment revenue | Pharmaceuticals Business 4,324 Millions of yen (YoY +12.8%), Infection Control Business 261 Millions of yen (YoY -33.1%), Other Business 3 Millions of yen |
| Segment profit | Pharmaceuticals Business 935 Millions of yen (YoY -14.6%), Infection Control Business -79 Millions of yen, Other Business -23 Millions of yen |
| Regional sales | 2,387 Millions of yen (YoY -12.2%), 1,937 Millions of yen (YoY +73.5%), 106 Millions of yen, 119 Millions of yen, 35 Millions of yen |
| Depreciation and amortization | 227 Millions of yen |
| Impairment loss | 0 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income None / Extraordinary loss Loss on disposal of fixed assets 1 Millions of yen, Impairment Losses 0 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable items |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New None / Excluded None / Company name None |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable None / Subject person Not disclosed |
| Issued Shares at Period-End | 50,636,900 |
| Treasury Shares at Period-End | 328,825 |
| Factors Behind Changes in Business Performance | Higher revenue from the pharmaceutical business, increased advertising and sales promotion expenses, and the reversal of gains on the sale of investment securities, gains on the reversal of the foreign currency translation adjustment account and compensation received recorded in the same period of the previous year. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to higher revenue from the pharmaceutical business. Operating profit declined because the increase in selling, general and administrative expenses, mainly advertising and sales promotion expenses, exceeded the increase in gross profit. Profit attributable to owners of the parent declined, partly due to the reversal of special gains recorded in the same period of the previous year, including a ¥347 million gain on the sale of investment securities, a ¥140 million gain on the reversal of the foreign currency translation adjustment account, and ¥14 million in compensation received.